Literature DB >> 29684565

Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison.

Prashant Sharma1, Daniel A Pollyea1, Clayton A Smith1, Enkhtsetseg Purev1, Manali Kamdar1, Bradley Haverkos1, Daniel Sherbenou1, Rachel Rabinovitch1, Andrew Hammes1, Jonathan A Gutman2.   

Abstract

The "Minnesota" reduced-intensity conditioning (RIC) cord blood transplantation (CBT) regimen (standard RIC) of fludarabine (Flu) (200 mg/m2), cyclophosphamide (Cy) (50 mg/kg), and 200- or 300-cGy total body irradiation (TBI) is the most published RIC CBT regimen. Though well tolerated, high relapse rates remain a concern with this regimen. Intensification of conditioning may reduce relapse without increasing transplant-related mortality (TRM). We performed a retrospective cohort comparison of outcomes in adult patients who underwent first double-unit CBT with standard RIC as compared with the intensified regimen of Flu 150 mg/m2, Cy 50 mg/kg, thiotepa 10 mg/kg, and 400-cGy TBI (intensified RIC). Of the 99 patients studied, 47 received intensified RIC. Acute myelogenous leukemia was the major indication for transplant. The median age at transplant was 67 years (range, 24 to 74 years) and 54 years (range, 25 to 67 years) in standard RIC and intensified RIC, respectively. Median hematopoietic stem cell transplantation comorbidity index was 3 (range, 0 to 5) and 1 (range, 0 to 6) in the standard RIC and intensified RIC groups, respectively. Median follow-up among survivors was 22 months (range, 3.7 to 79 months) following standard RIC and 15 months (range, 2.8 to 36 months) following intensified RIC. The cumulative incidence (CI) of relapse was significantly lower following intensified RIC compared with standard RIC (P = .0013); this finding maintained significance in multivariate analysis (P = .045). TRM was comparable between the 2 groups (P = .99). Overall survival (OS) was significantly improved following intensified RIC as compared with standard RIC (P = .03). Median OS was 17 months following standard RIC versus not reached followed intensified RIC. The CI of grade II to IV acute graft-versus-host disease (GVHD) was significantly higher in the intensified RIC cohort than the standard RIC-cohort (P = .007), while CI of grade III to IV acute GVHD, any chronic GVHD, and moderate-to-severe chronic GVHD was comparable in each cohort (P = .20, P = .21, and P = .61, respectively). This retrospective analysis shows an improvement in OS and decreased relapse without increase in TRM in patients receiving intensified RIC as compared with standard RIC. Our data suggest that consideration of thiotepa-based intensified RIC may improve outcomes in fit, older patients undergoing double-unit CBT.
Copyright © 2018 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cord blood transplantation; Intensified RIC; Reduced intensity conditioning; Thiotepa

Mesh:

Substances:

Year:  2018        PMID: 29684565     DOI: 10.1016/j.bbmt.2018.04.019

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  4 in total

1.  Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant.

Authors:  Prashant Sharma; Enkhtsetseg Purev; Bradley Haverkos; Daniel A Pollyea; Evan Cherry; Manali Kamdar; Tomer Mark; Peter Forsberg; Daniel Sherbenou; Andrew Hammes; Rachel Rabinovitch; Clayton A Smith; Jonathan A Gutman
Journal:  Blood Adv       Date:  2020-05-26

2.  High progression-free survival after intermediate intensity double unit cord blood transplantation in adults.

Authors:  Juliet N Barker; Sean M Devlin; Kristine A Naputo; Kelcey Skinner; Molly A Maloy; Lisa Flynn; Theodora Anagnostou; Scott T Avecilla; Andromachi Scaradavou; Christina Cho; Parastoo B Dahi; Sergio A Giralt; Boglarka Gyurkocza; Alan M Hanash; Katharine Hsu; Ann A Jakubowski; Esperanza B Papadopoulos; Jonathan U Peled; Miguel-Angel Perales; Craig S Sauter; Gunjan L Shah; Brian C Shaffer; Roni Tamari; James W Young; Mikhail Roshal; Richard J O'Reilly; Doris M Ponce; Ioannis Politikos
Journal:  Blood Adv       Date:  2020-12-08

3.  Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia.

Authors:  Takaaki Konuma; Shohei Mizuno; Tadakazu Kondo; Yasuyuki Arai; Naoyuki Uchida; Satoshi Takahashi; Masatsugu Tanaka; Takuro Kuriyama; Shigesaburo Miyakoshi; Makoto Onizuka; Shuichi Ota; Yasuhiro Sugio; Yasushi Kouzai; Toshiro Kawakita; Hikaru Kobayashi; Yukiyasu Ozawa; Takafumi Kimura; Tatsuo Ichinohe; Yoshiko Atsuta; Masamitsu Yanada
Journal:  Blood Cancer J       Date:  2022-05-25       Impact factor: 9.812

4.  Cord-Blood Engraftment Using an Enhanced Dual-Conditioning Regimen for Malignant Hematologic Diseases.

Authors:  Jiahua Ding; Yongjun Fang; Rongfu Zhou; Yan Gu; Shengnan Du; Qin Lu; Qingqing Yue
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.